Alamar Biosciences (ALMR) Stock Price, News & Analysis

Company Overview

Alamar Biosciences, Inc. is a life sciences company developing technologies for highly sensitive protein detection and analysis. Its products are designed to help researchers identify and measure low-abundance biomarkers associated with diseases, including cancer, neurodegenerative disorders and immune-related conditions.

The company’s principal technology is the NULISA platform, which uses digital immunoassay methods to improve the sensitivity and multiplexing of protein biomarker analysis. Alamar offers NULISA-based products and workflows, including solutions for targeted protein panels and broader proteomic studies, as well as instrumentation and consumables intended for use by academic researchers, pharmaceutical companies and biotechnology organizations.

Alamar Biosciences is headquartered in Fremont, California, and its research-use products support biomarker discovery and translational research. The company was founded by Yuling Luo, who has served as its chief executive officer and has led the development of its protein analysis technology.

Key Stats

• Today's Range: $32.24 to $35.28
• 50-Day Range: $24.40 to $36.57
• 52-Week Range: $18.84 to $38.54
• Volume: 741,819 shs
• Average Volume: 456,799 shs
• Market Capitalization: $2.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.80
• Consensus Rating: Hold

Alamar Biosciences Stock Analysis - MarketRank™

Alamar Biosciences scored higher than 35% of companies evaluated by MarketBeat, and ranked 718th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Alamar Biosciences has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

Alamar Biosciences has a consensus price target of $31.80, representing about 6.7% downside from its current price of $34.07.

Amount of Analyst Coverage

Alamar Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alamar Biosciences are expected to grow in the coming year, from ($1.23) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alamar Biosciences is -17.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alamar Biosciences is -17.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.06% of the float of Alamar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Alamar Biosciences has a short interest ratio ("days to cover") of 7.95.

Change versus previous month

Short interest in Alamar Biosciences has recently increased by 0.05%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alamar Biosciences does not currently pay a dividend.

Dividend Growth

Alamar Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.93

News Sentiment

Alamar Biosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Alamar Biosciences this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for ALMR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

2 people have added Alamar Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alamar Biosciences insiders have not sold or bought any company stock.

Percentage Held by Institutions

Alamar Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ALMR
• CIK: 2104204
• Web: alamarbio.com
• Phone: (510) 626-9888
• Fax: 510-605-5062
• Employees: 222
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Alamar Biosciences: $31.80
• High Price Target: $35.00
• Low Price Target: $27.00
• Potential Upside/Downside: -6.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 11.85
• Quick Ratio: 10.23

Sales & Book Value

• Annual Sales: $74.21 million
• Price / Sales: 31.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 69,390,000
• Free Float: N/A
• Market Cap: $2.36 billion
• Optionable: N/A
• Beta: N/A